Evoke Pharma (EVOK)
(Delayed Data from NSDQ)
$0.47 USD
-0.05 (-10.13%)
Updated Jun 14, 2024 03:51 PM ET
After-Market: $0.48 +0.01 (1.72%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Evoke Pharma, Inc. [EVOK]
Reports for Purchase
Showing records 61 - 79 ( 79 total )
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Phase 3 Enrollment Complete, Top-Line Data Release Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Q4 cash burn better than forecast, 93% enrolled - reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
2015 Results Reported; Funded Through 2H 2016 Phase 3 Data Release; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
2015 Results Reported; Funded Through 2H 2016 Phase 3 Data Release; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Phase 3 Data Around the Corner; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Phase 3 Data Around the Corner; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Reports 3Q15 Financial Results; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Evoke Reports 3Q15 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Q3 cash burn better than forecast, enrollment on track, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Initiating Coverage with Buy and $27.00 Price Target
Provider: Rodman & Renshaw, Co.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Moving Metoclopramide Forward; Initiating Coverage with Buy and $27.00 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Q2 cash burn better than forecast, but enrollment has slowed, lower target to $13.75
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Q1 spending as expected, EVK-001 Phase 3 enrollment on pace for Q4 completion
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Q4 spending in check, EVK-001 one of few late-stage GI assets remaining
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Cardiac safety study successful, reiterate STRONG BUY, $16.00 price target
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Q2 reported, Phase 3 study enrolling, reiterate STRONG BUY, $16.00 price target
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Reports Q2, Phase 3 study enrolling, reiterate STRONG BUY, $16.00 price target
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
Reports Q1, Phase 3 study enrolling, reiterate STRONG BUY, $16.00 price target
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Evoke Pharma, Inc.
Industry: Medical - Generic Drugs
an easy risk to stomach, initiate with STRONG BUY, $16.00 price target
Provider: FELTL & COMPANY
Analyst: HAYNOR B